- Anika Therapeutics (NASDAQ:ANIK -0.1%) commences the U.S. commercial soft launch of TACTOSET, an injectable hyaluronic acid-enhanced bone repair therapy for bone voids and other bone defects caused by trauma or age-related degeneration.
- The launch is the company's first under its U.S.-based hybrid commercial model.
- Management will be discussing the launch at its Analyst and Investor Day today.
Anika launches regenerative therapy for bone repair in U.S.
Recommended For You
More Trending News
About ANIK Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| ANIK | - | - |
| Anika Therapeutics, Inc. | ||